Rising incidence of hepatocellular carcinoma in the United States

scientific article published on 01 March 1999

Rising incidence of hepatocellular carcinoma in the United States is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJM199903113401001
P698PubMed publication ID10072408

P2093author name stringMason AC
El-Serag HB
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectUnited States of AmericaQ30
hepatocellular carcinomaQ1148337
P304page(s)745-750
P577publication date1999-03-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleRising incidence of hepatocellular carcinoma in the United States
P478volume340

Reverse relations

cites work (P2860)
Q49097732(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study
Q3923379914-kDa Phosphohistidine phosphatase plays an important role in hepatocellular carcinoma cell proliferation
Q4058529115-Deoxy-delta12,14-prostaglandin J2, a ligand for peroxisome proliferators-activated receptor-gamma, induces apoptosis in human hepatoma cells
Q304966963-D modeling of the thermal coagulation necrosis induced by an interstitial ultrasonic transducer
Q42857965A Life-Saving Cancer: More on the Double Whammy
Q43484980A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria
Q37270468A Taiwanese Propolis Derivative Induces Apoptosis through Inducing Endoplasmic Reticular Stress and Activating Transcription Factor-3 in Human Hepatoma Cells
Q34024535A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma
Q27473000A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades
Q35068672A highly sensitive x-ray imaging modality for hepatocellular carcinoma detection in vitro
Q34611637A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas
Q33581156A novel biomarker TERTmRNA is applicable for early detection of hepatoma
Q33265633A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
Q50115050A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Q40351843A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma.
Q46574374A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma
Q38428175A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
Q39922106A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
Q44930012A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma
Q33343204A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
Q83311261A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma
Q49467808A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma
Q24544663A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma
Q46081574A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma.
Q40224948A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma
Q36859211A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland.
Q41439920A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma
Q43292659A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C.
Q44442215A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma
Q35032965A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
Q34126254A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection
Q104795075ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway
Q55035513AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.
Q37488688Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma.
Q38337088Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors
Q30448846Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma
Q36905691Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
Q45873421Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.
Q45880013Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice
Q40005823Adherence, internalization, and persistence of Helicobacter pylori in hepatocytes
Q86193896Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion
Q37002609Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma
Q75338998Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria
Q37122717Advances in experimental and translational research in the treatment of hepatocellular carcinoma
Q39917877Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention
Q34359674Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma
Q38161848After the cure: management of HCV after achievement of SVR.
Q44135489Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy
Q34575223Alcohol and hepatitis C.
Q34170359Alcohol-induced liver disease
Q40707188Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma.
Q91617824All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized co
Q35976258Alopecia: a common paraneoplastic manifestation of cholangiocarcinoma in humans and animals
Q36595263Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells.
Q37246570Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma
Q35231839Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume
Q44088366Altered androgen metabolism eventually leads hepatocellular carcinoma to an impaired hormone responsiveness
Q58700934Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials
Q37665692Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
Q34463052An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus
Q50710892An epidemiologic study of hepatocellular carcinoma in Canada.
Q33391857An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Q42131309An unusual initial presentation of hepatocellular carcinoma as a sellar mass.
Q34035767Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection
Q37729493Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines
Q28344359Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors
Q37364223Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
Q88574991Antineoplastic influence of nimesulide in chemically induced hepatocellular carcinoma by inhibition of DNA synthesis
Q35780838Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival
Q39036885Approach to Solid Liver Masses in the Cirrhotic Patient
Q37246194Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma
Q39503929Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production
Q94314421Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas
Q35776195Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study
Q33833557Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis
Q33946441Biological impact of geometric uncertainties: what margin is needed for intra-hepatic tumors?
Q28533447Biological networks for predicting chemical hepatocarcinogenicity using gene expression data from treated mice and relevance across human and rat species
Q57945502Blue green algal (cyanobacterial) toxins, surface drinking water, and liver cancer in Florida
Q36920698Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept
Q40359283Brain metastases from hepatocellular carcinoma in US patients
Q37461714Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker
Q36690763Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis
Q26770014CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review
Q36324498CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function
Q34544245CT in hepatic cirrhosis and chronic hepatitis
Q34681040CT perfusion of the liver: principles and applications in oncology
Q37072699CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial.
Q54999032CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Q37797702Cancer Epigenome
Q33386598Cancer biomarker AKR1B10 and carbonyl metabolism.
Q34402117Cancer burden in the year 2000. The global picture
Q45966861Cancer-associated molecular signature in the tissue samples of patients with cirrhosis.
Q80510550Cancers of the large bowel and hepatobiliary tract
Q81086290Cancers of the large bowel and hepatobiliary tract
Q33295308Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum
Q39700274Case-control study of the RFA therapeutic effect of newly developed 4D US and conventional 2D US.
Q35545730Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells
Q53487540Causes of death in patients with unresectable hepatocellular carcinoma.
Q37249594Cerebral and pulmonary embolisms after transcatheter arterial chemoembolization for hepatocellular carcinoma
Q75339016Challenging choices: liver transplantation for hepatocellular carcinoma
Q37278046Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion.
Q36179782Changes in survival patterns in urban Chinese patients with liver cancer
Q50744502Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan.
Q33962674Changing international trends in mortality rates for liver, biliary and pancreatic tumours
Q54462115Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients.
Q64232007Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea
Q37262038Characteristics of common solid liver lesions and recommendations for diagnostic workup
Q41518564Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma
Q80114603Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles
Q38391223Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial
Q78418406Chemoembolization for hepatocellular carcinoma: where does the truth lie?
Q45737041Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus
Q26772302Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents
Q35101365Chemopreventive strategies in hepatocellular carcinoma
Q34067946Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
Q42457047Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.
Q78690345Cholangiocarcinoma: the "other" liver cancer on the rise
Q77129344Chronic Hepatitis C
Q34137291Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit
Q44767670Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics
Q37278061Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies
Q35628134Chronic hepatitis C in African Americans and other minority groups
Q37148328Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Q44759300Chronic liver disease mortality in the United States, 1990-1998.
Q33746278Cirrhosis of liver.
Q52087746Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.
Q35163337Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans
Q35289603Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
Q43686220Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?
Q36016030Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma
Q89750132Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread:
Q84273456Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma
Q44038010Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study.
Q34357073Clinical implications of cancer stem cell biology in hepatocellular carcinoma
Q29616866Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver
Q85283149Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma
Q51643325Clinical trials and their translation in hepatology: past, present, and future.
Q42278956Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population
Q45739008Clinicopathological determinants of survival after hepatic resection of hepatocellular carcinoma in 97 patients--experience from an Australian hepatobiliary unit
Q45036838Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma
Q35010409Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma
Q36612365Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma
Q31157318Cluster of liver cancer and immigration: a geographic analysis of incidence data for Ontario 1998-2002.
Q53089521Combination of sulfamethoxazole and selenium in anticancer therapy: a novel approach.
Q82742558Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma
Q40339271Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion
Q38197831Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis
Q36638136Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma
Q34093354Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model
Q36519015Comparative and integrative functional genomics of HCC.
Q38353727Comparative effectiveness in hepatic malignancies
Q33728023Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease
Q51703108Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?
Q42143353Comparison between the treatment area of electrode used for radiofrequency ablation of liver cancer focusing on 15G cooled-tip and CWT electrode
Q40553758Comparison of Clinicopathologic Characteristics and Outcomes After Resection in Patients With Hepatocellular Carcinoma Treated in the United States, France, and Japan
Q42999544Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis
Q35942016Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis
Q79925712Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma
Q81577003Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells
Q44447714Computed tomography-guided transarterial chemoembolization as the initial therapy for hepatocellular carcinoma: experience of 75 cases in a single institute
Q30483902Computer-aided diagnosis for the classification of focal liver lesions by use of contrast-enhanced ultrasonography
Q34522010Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.
Q41659507Contemporary strategies in the management of hepatocellular carcinoma
Q34617414Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
Q30478164Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocellular carcinoma
Q56985572Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis
Q35658940Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Q50710789Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma.
Q45525964Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis
Q40780468Cost-effectiveness of treatments for chronic hepatitis C.
Q34539948Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
Q89474143Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update
Q92276626Current and Future Systemic Therapies for Hepatocellular Carcinoma
Q34623730Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review
Q38158226Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea
Q37072518Current management of advanced hepatocellular carcinoma
Q84121761Current management of hepatocellular cancer
Q57756921Current management of liver cancer
Q43093342Current management strategy of hepatocellular carcinoma
Q34982945Current perspectives in cancer proteomics
Q34593957Current status of liver transplantation for hepatocellular cancer
Q40014368Current status of therapy for hepatocellular carcinoma
Q33951473Current therapy for chronic hepatitis C.
Q79424117Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States
Q40275006Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma
Q39047929DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques.
Q36382856Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells
Q82392060Deaths on the liver transplant waiting list: an analysis of competing risks
Q37431536Decoding human liver cancer signatures.
Q35870767Decreased PCSK9 expression in human hepatocellular carcinoma.
Q34958488Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity
Q37714088Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C
Q53121903Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases.
Q49202205Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway
Q73234099Delayed liquid gastric emptying in patients with hepatocellular carcinoma
Q30738437Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries.
Q37278212Demographics of a large cohort of urban chronic hepatitis C patients
Q28201418Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients
Q36577658Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells
Q33410061Detection of hepatocellular carcinoma using glycomic analysis
Q47441957Detection of identical Helicobacter DNA in the stomach and in the non-cirrhotic liver of patients with hepatocellular carcinoma
Q52672723Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population.
Q30488488Detoxification of Aflatoxin-Contaminated Maize by Neutral Electrolyzed Oxidizing Water.
Q36746850Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma
Q37380388Development of novel treatments for hepatitis C.
Q37015632Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma
Q34555816Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study
Q34547411Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma
Q34098835Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring
Q80850379Diagnosis of hepatocellular carcinoma
Q39213771Diagnosis of hepatoma using grayscale and Doppler ultrasound in patients with chronic liver disease
Q37577551Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.
Q35270302Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma
Q33788058Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States
Q79823799Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening
Q35052730Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients.
Q38768256Disease monitoring of hepatocellular carcinoma through metabolomics
Q34422414Disparities in Liver Cancer Incidence by Nativity, Acculturation, and Socioeconomic Status in California Hispanics and Asians
Q36806996Disparities in liver transplantation before and after introduction of the MELD score
Q35740123Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer
Q27489928Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma
Q46059193Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma
Q34083775Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?
Q74402233Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma?
Q30426959Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma?
Q24685704Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma
Q40175472Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis.
Q45323756Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study
Q43078745Drug therapy: sorafenib
Q34391996Drug treatment of the complications of cirrhosis in the older adult
Q24187663Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma
Q24202061Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma
Q35207490Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection
Q58236150Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience
Q33280446Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system
Q36348796Early liver cancer: concepts, diagnosis, and management
Q35736527Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort
Q33742856Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
Q40279496Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population
Q40950784Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection
Q37478899Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver
Q28361953Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
Q54616826Effect of sorafenib on murine liver regeneration.
Q33977186Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients
Q43138169Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice
Q34583094Effects and mechanisms of silibinin on human hepatoma cell lines
Q41910185Effects of blueberries on migration, invasion, proliferation, the cell cycle and apoptosis in hepatocellular carcinoma cells
Q53102584Effects of implementing an "enhanced recovery after surgery" program on patients undergoing resection of hepatocellular carcinoma.
Q37002698Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma
Q46468589Efficacy of hepatocellular carcinoma locoregional therapies on patients waiting for liver transplantation.
Q43031055Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone
Q34017814Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study
Q90602411Elastic Net Constrained Stereotype Logit Model for Ordered Categorical Data
Q81342006Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival
Q34533357Embolisation of cancer: what is the evidence?
Q28391490Endoplasmic reticulum stress activates the hepatic activator protein 1 complex via mitogen activated protein kinase-dependent signaling pathways
Q42701066Endoscopic Ultrasound -guided Fine-Needle Aspiration of a Portal Vein Thrombus to Aid in the Diagnosis and Staging of Hepatocellular Carcinoma.
Q24628144Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
Q90458437Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo
Q34076490Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells
Q40600354Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway
Q36365466Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation.
Q37241377Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States
Q34527770Epidemiology and clinical presentation of hepatocellular carcinoma
Q73541726Epidemiology of hepatocellular carcinoma
Q78726781Epidemiology of hepatocellular carcinoma
Q80426424Epidemiology of hepatocellular carcinoma in Bas-Rhin: analysis of all incident cases from 1990 to 1999
Q80066047Epidemiology of hepatocellular carcinoma in Finistère. Prospective study from June 2002 to May 2003
Q36519002Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity
Q36411144Epigenetic instability and chromosomal instability in hepatocellular carcinoma
Q92001987Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis
Q43049278Epstein-Barr virus and human hepatocellular carcinoma
Q30831603Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98.
Q41690819Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome
Q36415612Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.
Q73073538Estimating future hepatitis C morbidity, mortality, and costs in the United States
Q35171592Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm.
Q80463938Ethnic differences in hepatocellular carcinoma: implications for liver transplantation
Q87620289Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy
Q34394471Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma.
Q37290714Evolving therapies in the treatment of hepatocellular carcinoma
Q42496570Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma
Q28191190Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma
Q44794722Experiences in liver transplantation for hepatocellular carcinoma
Q40036988Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo
Q35011207Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma
Q43889420Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro
Q43585856Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma
Q54215487Expression of cytoskeleton regulatory protein Mena in human hepatocellular carcinoma and its prognostic significance.
Q43076650Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma
Q33648955Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma
Q28481696Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway
Q35597331Extrahepatic biliary obstruction after percutaneous tumour ablation for hepatocellular carcinoma: aetiology and successful treatment with endoscopic papillary balloon dilatation.
Q81120947Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection
Q43924482Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy
Q42877691Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma
Q37613015Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients
Q35195272Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C
Q58108213Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma
Q35699313Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma
Q36363383Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43.
Q30235178Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
Q35207733Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians
Q28550036Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma
Q27490242Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma
Q37790070Gene signatures in hepatocellular carcinoma (HCC).
Q40644810Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3.
Q35208038Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact
Q45865909Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene
Q27487515Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma
Q34624434Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis
Q42258048Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection.
Q41918713Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma
Q34764430Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation
Q37500885Genomic profiling of liver cancer
Q33399464Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma
Q44041035Geographic variation within the United States in the incidence of hepatocellular carcinoma
Q37466205Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas.
Q27860799Global epidemiology of hepatitis C virus infection
Q36002022Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure.
Q50176311Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells
Q38366329Glycosylation and liver cancer
Q36124126Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma
Q40977209Graph cut liver segmentation for interstitial ultrasound therapy
Q34544239Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening, and intervention
Q50472148Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma.
Q53652121Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography.
Q34532749Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults
Q81898519HA/GSA-Rmax ratio as a predictor of postoperative liver failure
Q83078598HBV-related HCC, clinical issues and therapy
Q30245486HIV, Aging, and Viral Coinfections: Taking the Long View.
Q90423329HNF4α-Deficient Fatty Liver Provides a Permissive Environment for Sex-Independent Hepatocellular Carcinoma
Q43637077HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
Q38642356Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model
Q36239313Health care reform: how personalized medicine could help bundling of care for liver diseases
Q37249688Health disparities in liver disease: Time to take notice and take action
Q35538156Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006.
Q36644408Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies
Q37352004Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets
Q33344056Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases
Q36180460Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
Q33604270Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma
Q28202929Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes
Q38410821Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
Q42685478Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria
Q36332915Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality
Q45723125Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma?
Q44464287Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection
Q36815013Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis
Q37627088Hepatitis B and C in African Americans: current status and continued challenges
Q35045196Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients
Q43079078Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma
Q35595027Hepatitis C and HIV-1 coinfection
Q57724630Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients
Q34228398Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma
Q33934023Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system
Q39345427Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling
Q33516543Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers
Q34542083Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status.
Q22305832Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies
Q36111060Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma
Q24631773Hepatobiliary MR imaging with gadolinium-based contrast agents
Q34336505Hepatocellular Carcinoma 11 and a Half Years after the Resolution of Chronic Hepatitis C Virus Infection Successfully Treated with Interferon
Q64109847Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States
Q26781798Hepatocellular Carcinoma and Liver Transplantation: State of the Art
Q60951670Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis
Q34131801Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
Q48268747Hepatocellular Carcinoma: Surgical Management and Evolving Therapies
Q29615841Hepatocellular carcinoma
Q57696098Hepatocellular carcinoma
Q74267144Hepatocellular carcinoma
Q93930900Hepatocellular carcinoma
Q39027102Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review.
Q39754997Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI.
Q35362361Hepatocellular carcinoma in Central Europe: prognostic features and survival
Q35059721Hepatocellular carcinoma in Egypt: a single center study over a decade.
Q35741066Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency
Q44124162Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy
Q75211784Hepatocellular carcinoma in liver transplant era: a clinicopathologic analysis
Q34255487Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
Q36512811Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008.
Q34084962Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis
Q36310075Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in Korean patients older than 70 years
Q53824769Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study.
Q83053433Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis
Q37015123Hepatocellular carcinoma prevalence and mortality in a male state prison population
Q48015576Hepatocellular carcinoma surveillance: The road ahead
Q80448247Hepatocellular carcinoma with isolated left adrenal metastasis following liver transplantation
Q34512068Hepatocellular carcinoma--cause, treatment and metastasis
Q36579533Hepatocellular carcinoma--rising incidence, changing therapeutic strategies
Q27489394Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis
Q35507289Hepatocellular carcinoma: HCC
Q78032946Hepatocellular carcinoma: a prime indication for living donor liver transplantation
Q35193283Hepatocellular carcinoma: are we making progress?
Q36108310Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review
Q37355835Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
Q34633249Hepatocellular carcinoma: insight from animal models
Q35196709Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Q36687672Hepatocellular carcinoma: molecular biology and therapy
Q36914691Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy
Q34756070Hepatocellular carcinoma: predisposing conditions and precursor lesions
Q35068060Hepatocellular carcinoma: present status and future prospects
Q34409128Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.
Q44890377Hepatocellular carcinoma: strategy for optimizing surgical resection, transplantation and palliation
Q35174436Hepatocellular carcinoma: surgical indications and results
Q36377949Hepatocellular carcinoma: therapy and prevention
Q35628112Hepatocellular carcinoma: updates in primary prevention
Q51665999Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.
Q35507576Hepatocellular recurrence after orthotopic liver transplantation: Is combination of α-fetoprotein and glypican-3 a reliable marker?: Hepatocellular recurrence after orthotopic liver trasplantation.
Q40639511Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences
Q30376715High correlation between microbubble contrast-enhanced ultrasound, magnetic resonance and histopathology in the evaluation of hepatocellular carcinoma.
Q34500720High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients.
Q44746125High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population
Q37565602High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization.
Q34156818Hospital-based, acute care encounters after radiofrequency ablation of hepatic tumours
Q58703392Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B
Q38083250Human hepatocyte carcinogenesis (review).
Q24301818Human homologue of maid is a useful marker protein in hepatocarcinogenesis
Q35103419Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma
Q37131434Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes
Q57634858Identification and characterization of CRG-L2, a new marker for liver tumor development
Q33591504Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods
Q44305778Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells
Q74434735Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma
Q30433998Image-guided non-invasive ultrasound liver ablation using histotripsy: feasibility study in an in vivo porcine model
Q37370024Image-guided percutaneous ablation therapies for hepatocellular carcinoma
Q34922580Imaging evaluation of hepatocellular carcinoma
Q80351857Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat
Q80475287Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies
Q33976481Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma
Q34148593Immunopathogenesis of hepatitis C virus in the immunosuppressed host
Q37144014Immunotherapy for liver tumors: present status and future prospects.
Q35625989Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial
Q53487180Impact of preoperative planning using virtual segmental volumetry on liver resection for hepatocellular carcinoma.
Q43778834Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.
Q43436743Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria
Q35207762Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC.
Q37229285In search of liver cancer stem cells.
Q39939752In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells
Q38828541Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma
Q33939214Incidence and mortality rates of selected infection-related cancers in Puerto Rico and in the United States
Q36812718Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma.
Q35363829Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.
Q58750606Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage
Q35077956Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice
Q30813397Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus
Q40679375Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma
Q33797399Increased mortality from liver cancer in England and Wales is not related to hepatitis C.
Q53490169Increased vascular endothelial growth factor transcription in residual hepatocellular carcinoma after open versus laparoscopic hepatectomy in a small animal model.
Q64378773Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization
Q51037580Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma.
Q37002196Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics
Q42987726Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population
Q36695203Inherent growth advantage of (pre)malignant hepatocytes associated with nuclear translocation of pro-transforming growth factor alpha.
Q30576918Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
Q44071055Inhibition of rat hepatocellular carcinoma tumor growth after multiple infusions of recombinant Ad.AFPtk followed by ganciclovir treatment
Q47424080Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors
Q46082144Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation
Q41128742Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma
Q73979679Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach
Q42168851Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients
Q44286199Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy
Q35177884International trends in primary liver cancer incidence from 1973 to 2007.
Q40692505Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin
Q33785906Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center
Q35915311Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?
Q61971049Is radiofrequency ablation an effective long-term treatment for early-stage hepatocellular carcinoma?
Q38029966Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis
Q44230423Is there a causal link between hepatitis B vaccination and multiple sclerosis?
Q39580008Isatis indigotica induces hepatocellular cancer cell death via caspase-independent apoptosis-inducing factor translocation apoptotic pathway in vitro and in vivo.
Q28280015KIAA0008 gene is associated with invasive phenotype of human hepatocellular carcinoma--a functional analysis
Q40161488KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis
Q33729947Knowledge and perceptions of hepatitis C infection and pesticides use in two rural villages in Egypt
Q36349931Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists
Q36296534Knowledge of viral hepatitis among Puerto Rican adults: implications for prevention
Q33706739Lamivudine. A review of its therapeutic potential in chronic hepatitis B.
Q33237223Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives
Q43248970Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up
Q34108430Laser ablation for small hepatocellular carcinoma.
Q35370564Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives
Q35154369Late recurrence of hepatocellular carcinoma after liver transplantation
Q33823239Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma
Q35435112Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma
Q80673326Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment
Q36917485Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.
Q33903328Little response of cerebral metastasis from hepatocellular carcinoma to any treatments
Q42320233Liver Imaging Reporting and Data System: an expert consensus statement
Q40598063Liver Resection for De Novo Hepatocellular Carcinoma Complicated by Pyogenic Liver Abscess: A Clinical Challenge
Q33871866Liver Transplantation for Hepatocellular Carcinoma among African Americans in the United States
Q41872601Liver cancer imaging: role of CT, MRI, US and PET.
Q40730798Liver carcinoma prevention among Asian Pacific Islanders. Getting hepatitis B shots into arms
Q35621256Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma
Q37347288Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma
Q44136661Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
Q43148137Liver stem cells and molecular signaling pathways in hepatocellular carcinoma
Q30470829Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis.
Q37625817Liver transplantation after radioembolization in a patient with unresectable HCC.
Q24672943Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA
Q58541779Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison
Q78625642Liver transplantation for hepatocellular carcinoma: an Asian perspective
Q39739700Liver transplantation for hepatocellular carcinoma: an update.
Q39067623Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Q36104785Liver transplantation for hepatocellular carcinoma: the ochsner experience
Q77959039Liver transplantation in the therapy of hepatocellular carcinoma: a revision of our series
Q33531442Liver tumour segmentation using contrast-enhanced multi-detector CT data: performance benchmarking of three semiautomated methods.
Q39376301Liver vessels segmentation using a hybrid geometrical moments/graph cuts method.
Q37708048Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison
Q37382536LncRNA CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR-384.
Q26745962Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy
Q32059980Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies
Q47415758Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma
Q31046676Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective
Q58021730Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care
Q53211913Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Q46118329Long-term efficacy of percutaneous thermal ablation for patients with recurrent hepatocellular carcinoma
Q37780114Long-term experience with liver transplantation for hepatocellular carcinoma
Q45347565Long-term outcome of liver transplantation as treatment modality in patients with hepatocellular carcinoma in cirrhosis: a single-center experience
Q56775925Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma
Q46379731Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors
Q77847343Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters
Q77739119Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation
Q43525135Longer survival in female than male with hepatocellular carcinoma
Q34394479Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre
Q37277822Loss of RhoGDI is a novel independent prognostic factor in hepatocellular carcinoma
Q33785451Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis
Q53304862MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers.
Q84152531MR elastography of the liver at 3 T with cine-tagging and bending energy analysis: preliminary results
Q78073632MR imaging of hepatocellular carcinoma
Q35083377MR imaging of liver tumors
Q39975299MRI in detection of hepatocellular carcinoma (HCC).
Q37724698MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma.
Q35409507Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74
Q34544251Magnetic resonance of focal liver lesions in hepatic cirrhosis and chronic hepatitis
Q37247967Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma.
Q74475105Malignant liver tumors
Q37096576Malignant liver tumors in South African children: a national audit
Q26864406Management of "very early" hepatocellular carcinoma on cirrhotic patients
Q26797581Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law
Q29616230Management of hepatocellular carcinoma
Q83816502Management of hepatocellular carcinoma
Q36955647Management of hepatocellular carcinoma: Enlightening the gray zones.
Q26997063Management of recurrent hepatocellular carcinoma after liver transplant
Q35081063Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation
Q38164705Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato-gastric fistula
Q34449667Mechanisms of alcohol-induced hepatocellular carcinoma
Q38059437Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Q39817753Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines
Q34782084Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway.
Q33443502Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma
Q35201755Metastatic hepatocellular carcinoma
Q36806323Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer
Q35028814MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule
Q28743220MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria
Q39897190MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma
Q29547523MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer
Q37381107MicroRNAs as therapeutic targets in chemoresistance
Q79777704Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin
Q24312971Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis
Q42172816Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma
Q37328317Midkine: a novel prognostic biomarker for cancer
Q64098595Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression
Q74703072Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention
Q42872868Models of hepatocellular carcinoma and biomarker strategy
Q27480801Modulation of RANTES expression by HCV core protein in liver derived cell lines
Q33983949Molecular biology of hepatitis C infection
Q35048768Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?
Q36646497Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum
Q40390047Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11.
Q36618666Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis
Q39214067Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro
Q37003665Molecular targeted therapies in hepatocellular carcinoma
Q42998892Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality
Q35196596Molecular viral oncology of hepatocellular carcinoma
Q53621195Monitoring serial CD4⁺ T-cell function after liver transplantation can be used to predict hepatocellular carcinoma recurrence.
Q38935703Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
Q34922740Multidisciplinary management of hepatocellular carcinoma
Q43000237Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse.
Q37384682Multimodal approaches to the treatment of hepatocellular carcinoma
Q54112398Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma.
Q57168249Mutations of the HFE gene in patients with hepatocellular carcinoma
Q38296442N-linked glycosylation of the liver cancer biomarker GP73
Q28586911NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma
Q35110675Nanomaterials for X-ray imaging: gold nanoparticle enhancement of X-ray scatter imaging of hepatocellular carcinoma
Q28246583Nanotechnology: intelligent design to treat complex disease
Q44637697Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation
Q41129234Needle track seeding following percutaneous procedures for hepatocellular carcinoma
Q34953308Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials
Q37801938Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics
Q26749329New advances in hepatocellular carcinoma
Q33185268New interventions for liver tumors
Q33266698New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples
Q30448048New paradigm for management of hepatocellular carcinoma by imaging
Q43234592New pharmacological developments in the treatment of hepatocellular cancer
Q38742891Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model
Q41858920Non-Invasive Ultrasound Liver Ablation Using Histotripsy: Chronic Study in an In Vivo Rodent Model
Q82156525Non-alcoholic fatty liver disease: is iron relevant?
Q37564661Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention
Q49191881Non-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas
Q44892536Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy
Q34041381Non-viral causes of hepatocellular carcinoma
Q84989567Non-viral causes of hepatocellular carcinoma
Q34653639Non-viral factors contributing to hepatocellular carcinoma
Q37739949Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection
Q33381184Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Q32059984Nonsurgical treatment of hepatocellular carcinoma
Q90682200Novel Prognostic Scores Based on Plasma Prothrombin Time and Fibrinogen Levels in Patients With AFP-Negative Hepatocellular Carcinoma
Q43153295Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats.
Q40607428Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis
Q48120126Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology.
Q46161399Novel endothelial cell markers in hepatocellular carcinoma
Q83412968Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report
Q47547759Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC.
Q28073381Obesity-Related Digestive Diseases and Their Pathophysiology
Q40526582Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus
Q34557399Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines
Q38447668Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis
Q38081075Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes
Q36069902Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study
Q38197503Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells
Q92669063Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma
Q84104652Orthotopic liver transplantation for hepatocellular carcinoma: one center's experience in the Northeast of Brazil
Q34478383Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center
Q36273094Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma.
Q34130377Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma
Q38223402Outcomes after surgery for spinal metastasis of colorectal origin: case series
Q30431066Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
Q85050891Outcomes of non-anatomic liver resection for hepatocellular carcinoma in the patients with liver cirrhosis and analysis of prognostic factors
Q34293799Over-expression of the ribosomal protein L36a gene is associated with cellular proliferation in hepatocellular carcinoma
Q34053320Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis
Q24645168Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma
Q34100189Overexpression of tetraspanin CO-029 in hepatocellular carcinoma
Q36824960Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma
Q51378631PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline.
Q36330881PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice
Q36441150Particle embolization of recurrent hepatocellular carcinoma after hepatectomy.
Q35122985Pathologic spectrum and prognostic significance of underlying liver disease in hepatocellular carcinoma
Q44485326Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma
Q33788043Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation.
Q45735081Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis
Q36208355Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers
Q46873874Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
Q43040967Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
Q24186496Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
Q31128451Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future
Q33181403Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver
Q34390771Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases
Q81668582Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation
Q24240216Percutanous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
Q24244936Percutanous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
Q53241493Performance of radiological methods in diagnosing hepatocellular carcinoma preoperatively in a recipient of living related liver transplantation: comparison with step section histopathology.
Q37158120Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma
Q37495410Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
Q83292338Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
Q51778319Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.
Q44865180Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma
Q34593345Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Q33818746Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial
Q73060601Phyllanthus amarus extract administration increases the life span of rats with hepatocellular carcinoma
Q58114955Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis
Q80992032Pituitary and bilateral adrenal enlargement: an unusual presentation of hepatocellular carcinoma
Q34541065Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line
Q35584655Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma
Q41951864Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
Q34651625Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China
Q44895098Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers
Q40611976Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma
Q89668258Predict New Therapeutic Drugs for Hepatocellular Carcinoma Based on Gene Mutation and Expression
Q45728735Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning
Q79390690Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers
Q35715916Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus
Q36082172Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma
Q44636627Predictors and patterns of recurrence after resection of hepatocellular carcinoma
Q40376459Predictors of In-Hospital Mortality in patients with hepatocellular carcinoma and Acute Variceal bleeding
Q45961421Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma
Q45897134Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization
Q37130713Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation
Q28344083Preoperative galactose elimination capacity predicts complications and survival after hepatic resection
Q43725941Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.
Q78020869Preoperative predictors of survival after resection of small hepatocellular carcinomas
Q79249978Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol
Q33612167Present and future possibilities for early diagnosis of hepatocellular carcinoma
Q35535968Presentation and outcomes of hepatocellular carcinoma patients at a western centre
Q36550695Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection
Q51969974Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness.
Q42557069Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats
Q37196508Primary hepatocellular carcinoma and metabolic syndrome: An update
Q52815167Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B).
Q38464518Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival
Q35865620Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma
Q39468081Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC.
Q42256081Profile of hepatocellular carcinoma in a tertiary care hospital in Punjab in northern India
Q34037698Progenitor-derived hepatocellular carcinoma model in the rat.
Q73076619Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification
Q80059805Prognosis and results after resection of very large (>or=10 cm) hepatocellular carcinoma
Q34061430Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems
Q41497351Prognostic Factors and Clinical Characteristics for Hepatocellular Carcinoma Patients with Benign Enlarged Perihepatic Lymph Nodes: a Single-Center Experience from China
Q37178647Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma
Q58811104Prognostic features and survival of hepatocellular carcinoma in Italy
Q84183847Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy
Q46322238Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy
Q43693428Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma
Q54997186Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma.
Q58321632Prognostic significance ofc-myc andAIB1 amplification in hepatocellular carcinoma
Q40651059Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis
Q35169393Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma
Q92615766Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors
Q36456976Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma
Q40586760Prolylhydroxylase and procollagen type III in long-term survivors of acute lymphoblastic leukemia (ALL): a biochemical approach to HCV-related liver disease
Q36316587Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients
Q37586761Promoter methylation of SFRP3 is frequent in hepatocellular carcinoma
Q40263391Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma
Q27478125Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection
Q33387430Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [
Q36952594Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma
Q37235449Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation.
Q34609315Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study.
Q83811881Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma
Q33378135Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma
Q36519019Proteomics for the early detection and treatment of hepatocellular carcinoma
Q37403329Pulmonary metastases from primary hepatocellular carcinoma in a 26-year-old patient: a case report
Q36147024Quantitative assessment of washout in hepatocellular carcinoma using MRI.
Q34544494RETRACTED: Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis
Q55259186Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.
Q51734417Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma.
Q42985436Racial differences in liver inflammation and fibrosis related to chronic hepatitis C.
Q37095472Racial disparity in liver disease: Biological, cultural, or socioeconomic factors
Q46493966Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival
Q34565716Radiation therapy for hepatocellular carcinoma: from palliation to cure
Q36517404Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients
Q24201669Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma
Q83182890Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations
Q36537526Radiofrequency ablation in patients with primary and secondary hepatic malignancies.
Q37910079Radiofrequency ablation of high-grade dysplastic nodules
Q34702909Radiofrequency ablation of unresectable primary liver cancer
Q35166558Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials
Q41790928Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis.
Q82323058Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases
Q34547772Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma conforming to the Milan criteria: systemic review and meta-analysis
Q91791927Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis
Q37107230Radiofrequency ablation-assisted liver resection: review of the literature and our experience
Q47111617Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy.
Q35164855Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma.
Q58022064Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Q38186654Rare benign tumors of the liver: still rare?
Q44128719Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria
Q44764292Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study.
Q34821020Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players
Q55227929Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma.
Q48348464Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma
Q34483036Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma
Q51023061Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study.
Q53391613Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors.
Q39882641Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells
Q37316228Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
Q35167394Reproducibility of CT perfusion parameters in liver tumors and normal liver
Q42463320Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine
Q79074915Resection of Hepatocellular Carcinoma in Patients Otherwise Eligible for Transplantation
Q39001227Resection of T4 hepatocellular carcinomas with adjacent structures, is it justified?
Q33974096Resection prior to liver transplantation for hepatocellular carcinoma
Q37072527Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.
Q30379347Response of MiRNA-22-3p and MiRNA-149-5p to Folate Deficiency and the Differential Regulation of MTHFR Expression in Normal and Cancerous Human Hepatocytes
Q42199528Response to transarterial chemoembolization in candidates with hepatocellular carcinoma within Milan criteria does not predict post-transplant disease-free survival
Q35903837Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis
Q88177250Results of 15-Year Experience in Liver Transplant for Hepatocellular Carcinoma
Q33851416Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis
Q37450268Right adrenal metastases of hepatocarcinoma after liver transplantation: case report and literature review
Q34099104Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005).
Q35543614Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes
Q44903654Risk factors for hepatocellular carcinoma in patients with cirrhosis
Q38737134Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.
Q36006339Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model
Q80539045Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis
Q41983643Role of free radicals in liver diseases.
Q33866483Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients
Q37132635Role of methionine adenosyltransferase genes in hepatocarcinogenesis
Q41128609Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma
Q37487162Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results
Q31149403SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma.
Q24303537SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway
Q40741225Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma
Q46135283Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
Q37988322Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines
Q42980924Scope of worldwide hepatitis C problem
Q34162158Screening for cancer in viral hepatitis
Q34922603Screening for hepatocellular carcinoma
Q35594964Screening for hepatocellular carcinoma in cirrhosis
Q35540833Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness
Q30415026Selection for hepatic resection of colorectal liver metastases: expert consensus statement
Q33965865Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease
Q39562856Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells.
Q45401455Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy
Q53589917Selective portal vein clamping for radiofrequency ablation of hepatocellular carcinoma with portal vein invasion.
Q33248641Separate origins of hepatitis B virus surface antigen-negative foci and hepatocellular carcinomas in transgenic HBsAg (alb/psx) mice
Q40264763Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients
Q46682777Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease
Q35098539Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma
Q33640766Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4
Q35181045Serum messenger RNA as a biomarker and its clinical usefulness in malignancies.
Q102220362Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection
Q86630953Short- and long-term outcomes after salvage liver transplantation versus primary liver transplantation for hepatocellular carcinoma: a meta-analysis
Q36455499Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma
Q37809251Signaling Networks in Human Hepatocarcinogenesis—Novel Aspects and Therapeutic Options
Q28392002Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma
Q46456555Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis
Q39868832Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells
Q39294082Simultaneous treatment of unresectable hepatocelluar carcinoma and hepatic artery aneurysm, case report
Q39918641Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma
Q42260669Solitary Asymptomatic Thyroid Metastasis from Hepatocellular Carcinoma Detected by FDG-PET/CT.
Q38719335Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study
Q43194424Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
Q33590407Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study
Q38207487Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
Q34861218Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
Q37441574Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
Q39952324Sorafenib for the treatment of unresectable hepatocellular carcinoma
Q36680204Sorafenib for treatment of hepatocellular carcinoma: a systematic review
Q47646635Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study
Q39140861Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling
Q36708741Sorafenib: where do we go from here?
Q40750117Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping
Q35122991Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma
Q33947885Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6- methylguanine-DNA methyltransferase
Q47777632Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study
Q33833270Statin efficacy in the treatment of hepatitis C genotype I.
Q59150549Statins and metformin for chemoprevention of hepatocellular carcinoma
Q87068963Statins for prevention of hepatocellular cancer: one step closer?
Q37612864Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients
Q58564362Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation
Q40086254Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma.
Q36863488Strategies for the management of hepatocellular carcinoma
Q81412667Subcutaneous tumor seeding following needle core biopsy of hepatocellular carcinoma
Q51259014Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation.
Q38368535Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC.
Q37644935Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation
Q41143523Suppression of the Wnt signaling pathway may contribute to the inhibition of proliferation of human hepatocellular carcinoma SMMC-7721 cells by esculetin
Q44149115Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis
Q37715129Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis
Q37768894Surgical treatment of hepatocellular carcinoma: expert consensus statement
Q34469509Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations
Q36587304Surrogate markers of efficacy for medical treatment of viral hepatitis.
Q45415812Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival
Q85107768Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma
Q33405646Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation
Q37389331Survival of hepatocellular carcinoma in Puerto Rico
Q34225706Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition
Q41917123Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib
Q50575290Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.
Q33897458Symptom management in hepatocellular carcinoma
Q36262043Synchronous primary breast cancer and hepatocellular carcinoma in a male patient: a case report
Q39917875Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.
Q36871557Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver
Q33391168Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies
Q35078725TP53 and liver carcinogenesis.
Q36777331TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer
Q34321927Temporal changes in liver cancer incidence rates in Japan: accounting for death certificate inaccuracies and improving diagnostic techniques
Q38806970The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma
Q57001209The Emerging Role of MicroRNAs in Hepatocellular Carcinoma
Q60961386The Epigenetic Regulation of HCC Metastasis
Q47185810The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population
Q97644461The Loss of Masculine With Declined Serum DHT Is Associated With High Risk of Hepatocellular Carcinoma in Chinese Men
Q33179763The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996.
Q28071619The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma
Q38921949The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration.
Q46622652The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
Q47108317The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide
Q37421369The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004.
Q82249610The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma
Q34170288The current status of liver transplantation for primary hepatic malignancy.
Q38526752The effect of fasting on PET Imaging of Hepatocellular Carcinoma.
Q34523695The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
Q60929481The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer
Q31004882The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours
Q28362636The epidemiology of hepatitis C in a UK health regional population of 5.12 million
Q36892181The epidemiology of hepatitis C infection in the United States
Q30447686The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology
Q33575717The global burden of cancer: priorities for prevention
Q41928677The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
Q33365826The impact of new data in the treatment of advanced hepatocellular carcinoma
Q81547801The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma
Q37766943The importance of fatty liver disease in clinical practice
Q33323289The imprint of radiofrequency in the management of hepatocellular carcinoma
Q34617479The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
Q36473813The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area
Q36082428The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma
Q37854505The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists
Q26777478The mutational landscape of hepatocellular carcinoma
Q38503057The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection
Q33945047The prevalence of hepatitis C virus infection in Texas: implications for future health care
Q79756613The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma
Q90476643The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma
Q57560468The rise and fall in primary liver cancer mortality in Italy
Q36873299The role of contrast-enhanced ultrasound for focal liver lesion detection: an overview
Q45334263The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans
Q35234037The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus
Q46876312The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial
Q27477845The science, economics, and effectiveness of combination therapy for hepatitis C
Q45188223The survival and value of liver transplantation for liver carcinoma: a single-center experience
Q26738658Therapeutic Strategies in HCC: Radiation Modalities
Q33201409Therapeutic effect of photodynamic therapy using PAD-S31 and diode laser on human liver cancer cells
Q50247004Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma
Q36662565Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations
Q50457812Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients.
Q33403977Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma
Q35777269Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study
Q38022245Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review).
Q56371870Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis
Q24235977Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Q35797957Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study
Q58765170Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Q42379112Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma
Q33929310Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival
Q35207822Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study
Q37155118Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients
Q51766175Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection.
Q35085720Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma
Q33998674Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma
Q40428440Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration
Q46497661Transplantation for hepatocellular carcinoma in younger patients has an equivocal survival advantage as compared with resection
Q34630274Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
Q33635364Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection vs. Gamma Knife Radiosurgery vs. Whole Brain Radiation Therapy
Q35833142Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma
Q81154169Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study
Q44724936Treatment modalities in patients with hepatocellular carcinoma: a retrospective series in a single institution in Mexico
Q53648876Treatment of Hepatocellular Carcinoma.
Q35739061Treatment of hepatocarcinoma
Q57757025Treatment of hepatocellular carcinoma
Q44888545Treatment of hepatocellular carcinoma in the cirrhotic liver
Q35631429Treatment of hepatocellular carcinoma in the community: disparities in standard therapy
Q41830340Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology.
Q38236876Treatment of intermediate-stage hepatocellular carcinoma
Q47909976Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion
Q37544738Treatment options for hepatitis C and the rationale for low response rates in African Americans
Q83196334Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation
Q43905234Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.
Q46296781Trends in mortality from primary liver cancer in Europe
Q24651526Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001
Q33761751Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma
Q34021608Trends in waiting list registration for liver transplantation for viral hepatitis in the United States
Q37800793Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets
Q34605421Tumor vaccine against recurrence of hepatocellular carcinoma
Q41196091Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus.
Q33483712Twist expression promotes migration and invasion in hepatocellular carcinoma
Q37356216Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma
Q35596794Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study
Q34143512Underutilization of therapy for hepatocellular carcinoma in the medicare population
Q37383964Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.
Q40707598Up-regulation of dbpA mRNA in hepatocellular carcinoma associated with metabolic syndrome
Q35674315Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?
Q43042926Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions
Q36325322Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma
Q34224698Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples
Q42722250Usefulness of Real-Time 4D Ultrasonography during Radiofrequency Ablation in a Case of Hepatocellular Carcinoma
Q44577619Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas
Q90609144Utility of positron emission tomography-computed tomography scan in detecting residual hepatocellular carcinoma post treatment: Series of case reports
Q34733478V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials
Q30660492Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing
Q41234297Validation of different staging systems for hepatocellular carcinoma in a cohort of 249 patients undergoing radiotherapy
Q51674471Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver
Q36715087Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma
Q44088369Variant estrogen receptors and their role in liver disease.
Q34559088Variation in the risk for liver and gallbladder cancers in socioeconomic and occupational groups in Sweden with etiological implications
Q37564297Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature
Q42418559Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI?
Q35617324Viral hepatitis C.
Q21245597Viral hepatitis and hepatocellular carcinoma
Q34568619Viral hepatitis and liver cancer: the case of hepatitis C.
Q37281965Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma.
Q37216659Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival
Q35122983What surgeons should know about viral hepatitis and hepatocellular carcinoma
Q36388315Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention
Q34618851[(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma
Q52922062[HCC screening].
Q53466302[Imaging nodules within cirrhotic liver: how do I do it?].
Q80554209[Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]
Q80052042[Palliative treatment of hepatocellular carcinoma]
Q53225138[Primary liver tumors : hepatocellular versus intrahepatic cholangiocellular carcinoma].
Q74222020[Radiofrequency in the treatment of hepatocellular carcinoma]
Q53526177[Should we screen for hepatocellular carcinoma?].
Q82526787[Surgery of hepatobiliary tumors]
Q40553724alpha-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses
Q40733600gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin
Q34790217miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14.

Search more.